Immunic Sets April 14 Shareholder Vote on Critical Reverse Stock Split to Maintain Nasdaq Listing and Fulfill Financing Terms

summarizeSummary

Immunic, Inc. filed a definitive proxy statement, setting April 14, 2026, as the date for a special shareholder meeting to vote on a reverse stock split, which is crucial for Nasdaq compliance and fulfilling terms of a recent $200 million private placement.

check_boxKey Events

• Special Shareholder Meeting Scheduled

  A special meeting of stockholders will be held virtually on April 14, 2026, at 9:00 a.m. Eastern Standard time.

• Vote on Reverse Stock Split

  Shareholders will vote on authorizing the Board to amend the company's certificate of incorporation to effect a reverse stock split at a ratio between 1-for-10 and 1-for-30, with the Board currently anticipating a range not exceeding 1-for-20.

• Critical for Nasdaq Compliance

  The primary reason for the reverse stock split is to increase the per-share trading price to meet Nasdaq's Minimum Bid Price Requirement and avoid delisting, following a transfer to the Nasdaq Capital Market on January 7, 2026.

• Condition of Recent Private Placement

  Obtaining shareholder approval for the reverse stock split is an obligation under the $200 million private placement agreement entered into on February 12, 2026. Failure to approve would result in a breach of these terms, materially adversely affecting the company.

auto_awesomeAnalysis

This definitive proxy statement (DEF 14A) confirms the special meeting on April 14, 2026, for shareholders to vote on a reverse stock split. This vote is critical for Immunic, Inc. as it is a necessary step to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting. Furthermore, the company explicitly states that failure to obtain shareholder approval for the reverse stock split would constitute a breach of the terms of its recent $200 million private placement agreement, which would materially adversely affect its business and operations. The proposed reverse split ratio ranges from 1-for-10 to 1-for-30, with the Board anticipating a range not exceeding 1-for-20. This filing follows a preliminary proxy statement on February 20, 2026, and a series of recent events highlighting the company's financial and compliance challenges, including a transfer to the Nasdaq Capital Market and a significant private placement.